ATE142489T1 - Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen - Google Patents

Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen

Info

Publication number
ATE142489T1
ATE142489T1 AT91910048T AT91910048T ATE142489T1 AT E142489 T1 ATE142489 T1 AT E142489T1 AT 91910048 T AT91910048 T AT 91910048T AT 91910048 T AT91910048 T AT 91910048T AT E142489 T1 ATE142489 T1 AT E142489T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
pharmaceutically acceptable
glucaric acid
cellular hyperproliferation
Prior art date
Application number
AT91910048T
Other languages
English (en)
Inventor
Zbigniew Walaszek
Thomas J Slaga
Margaret Hanausek
Original Assignee
Zbigniew Walaszek
Thomas J Slaga
Margaret Hanausek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zbigniew Walaszek, Thomas J Slaga, Margaret Hanausek filed Critical Zbigniew Walaszek
Application granted granted Critical
Publication of ATE142489T1 publication Critical patent/ATE142489T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03Organic compounds
    • A23L29/035Organic compounds containing oxygen as heteroatom
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91910048T 1990-05-16 1991-05-15 Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen ATE142489T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52538490A 1990-05-16 1990-05-16

Publications (1)

Publication Number Publication Date
ATE142489T1 true ATE142489T1 (de) 1996-09-15

Family

ID=24093031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91910048T ATE142489T1 (de) 1990-05-16 1991-05-15 Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen

Country Status (7)

Country Link
US (2) US5364644A (de)
EP (2) EP0730862A1 (de)
JP (1) JPH06504259A (de)
AT (1) ATE142489T1 (de)
CA (1) CA2080818A1 (de)
DE (1) DE69122099T2 (de)
WO (1) WO1991018593A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE142489T1 (de) * 1990-05-16 1996-09-15 Zbigniew Walaszek Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
FR2693876A1 (fr) * 1992-07-24 1994-01-28 Vani Complément nutritif à base de micronutriments.
BE1006217A6 (fr) * 1992-09-10 1994-06-14 Steils Anne Epouse Gerome Boisson lactee enrichie de nutriments.
CA2089607C (en) * 1992-11-05 1997-11-04 Ranjit K. Chandra Nutritional supplement for the elderly
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
WO1995035038A1 (de) * 1994-06-20 1995-12-28 Peter Singer Diätetisches lebensmittel und dessen verwendung
US5626884A (en) * 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
US6069167A (en) * 1996-01-16 2000-05-30 University Technology Corporation Use of antioxidant agents to treat cholestatic liver disease
AU727225B2 (en) * 1997-01-27 2000-12-07 Takara Bio Inc. Tetrahydrofurans
AU6765798A (en) 1997-03-20 1998-10-12 Coventry Group, Ltd. Nutritional supplement for cardiovascular health
ITFI970184A1 (it) * 1997-07-30 1999-01-30 Menarini Farma Ind Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
GB2337933A (en) * 1998-06-04 1999-12-08 Stephen Bloor Treating or prophylaxis of smoking related diseases
US6245360B1 (en) * 1998-06-26 2001-06-12 John S. Markowitz Nutritional supplement
US6103733A (en) * 1998-09-09 2000-08-15 Bachmann; Kenneth A. Method for increasing HDL cholesterol levels using heteroaromatic phenylmethanes
WO2000067596A1 (en) * 1999-05-07 2000-11-16 Trustees Of Tufts College Immune stimulating dietary supplement and methods of use thereof
WO2000074701A2 (en) * 1999-06-05 2000-12-14 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
AT6714U1 (de) * 1999-08-17 2004-03-25 Hanzel Jaroslav Mittel zur prävention von jodmangel
GB0016452D0 (en) * 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
ES2168226B1 (es) * 2000-11-27 2003-09-16 Recuperat Ion Electrolitos S L Composicion que comprende sodio, potasio, calcio y magnesio.
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US6849613B2 (en) * 2001-08-29 2005-02-01 Kedar N. Prasad Multiple antioxidant micronutrients
US6562378B1 (en) * 2002-08-16 2003-05-13 Tsar Health Private Ltd. Nutritional supplement for adolescents
US6565891B1 (en) * 2002-08-23 2003-05-20 Tsar Health Private Ltd. Nutritional supplement for children
US7635469B2 (en) * 2002-08-28 2009-12-22 Premier Micronutrient Corporation Micronutrient formulations for hearing health
US20080020035A1 (en) * 2002-08-28 2008-01-24 Kedar Prasad Micronutrient formulations and related methods of manufacture
EP1737482A4 (de) * 2004-03-01 2010-09-15 Lumen Therapeutics Llc Zusammensetzungen und verfahren zur behandlung von krankheiten
GB2416981A (en) * 2004-08-13 2006-02-15 Nutraceuticals Ltd Premixes, flour enriched with same, mineral supplemented foodstuffs and methods of manufacture therefore.
US7628984B2 (en) * 2005-02-17 2009-12-08 Premier Micronutrient Corporation Micronutrient formulations for pulmonary and heart health
US20090250653A1 (en) * 2006-08-07 2009-10-08 Kiely Donald E Hydroxycarboxylic Acids and Salts
US7692041B2 (en) 2006-08-07 2010-04-06 The University Of Montana Method of oxidation using nitric acid
DE102006040456A1 (de) * 2006-08-25 2008-02-28 Constantin Nies Verzehrbare flächige Darreichungsform von Nahrungsergänzungsmitteln und/oder Arzneiwirkstoffen zur Ergänzung von fertigen oder halbfertigen Nahrungsmitteln
US7605145B2 (en) * 2006-11-20 2009-10-20 Premier Micronutrient Corporation Micronutrient formulations for treatment of diabetes mellitus
EP2221059B1 (de) * 2007-10-25 2018-01-17 Nutri Co., Ltd. Zusammensetzung zur reduzierung des blutspiegels von glukose, malondialdehyd-modifiziertem ldl, homocystein und/oder c-reaktivem protein
JP5775305B2 (ja) * 2007-11-15 2015-09-09 ザ ユニバーシティー オブ モンタナ ヒドロキシポリアミドゲル形成剤
AU2011326374B2 (en) 2010-11-11 2017-02-16 Rivertop Renewables, Inc. Corrosion inhibiting composition
CA2833374A1 (en) 2011-04-21 2012-10-26 Rivertop Renewables, Inc. Calcium sequestering composition
EP2925826A1 (de) 2012-11-28 2015-10-07 Rivertop Renewables Korrosionshemmende und gefrierpunktsenkende zusammensetzungen
US9670124B2 (en) 2013-03-13 2017-06-06 Rivertop Renewables, Inc. Nitric acid oxidation process
BR112015022284A2 (pt) 2013-03-13 2017-07-18 Rivertop Renewables Inc processos de oxidação de ácido nítrico melhorados
US9346736B2 (en) 2013-03-13 2016-05-24 Rivertop Renewables, Inc. Oxidation process
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
WO2021043884A1 (en) * 2019-09-05 2021-03-11 Société des Produits Nestlé S.A. Food compositions for lactating women
WO2021043883A1 (en) * 2019-09-05 2021-03-11 Société des Produits Nestlé S.A. Food compositions for lactating women
US11278520B2 (en) * 2020-03-31 2022-03-22 Sabine Hazan Method of preventing COVID-19 infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1066885A (en) * 1964-07-29 1967-04-26 Zh Tokyo Seikagaku Kenkyukai Therapeutic agent and compositions having the inhibitory action for ª‰-glucuronidase and method of inhibiting ª‰-glucuronidase
US3697287A (en) * 1969-01-28 1972-10-10 Morton Norwich Products Inc Amino acid food composition
DE2651947A1 (de) * 1976-11-13 1978-05-18 Koehler Valentin Mittel mit pharmazeutischer und/oder antimikrobieller wirksamkeit
FR2370471A1 (fr) * 1976-11-13 1978-06-09 Kohler Valentin Agents a base d'acide glucarique possedant une activite pharmaceutique et/ou anti-microbienne
US4751085A (en) * 1984-08-29 1988-06-14 Gaull Gerald E Human nutritional compositions containing taurine and vitamins and/or minerals
US4845123A (en) * 1985-08-05 1989-07-04 The Ohio State University Reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by sustained-release inhibitors of β-g
US4740373A (en) * 1986-05-27 1988-04-26 Usv Pharmaceutical Corporation Stabilization of multivitamin/trace elements formulations
US5008291A (en) * 1987-08-26 1991-04-16 Ohio State University Research Foundation Method and composition for achieving chemotherapeutic activity
US5010107A (en) * 1987-08-26 1991-04-23 Ohio State University Research Foundation Method and composition for achieving anticarcinogenic activity
US4997852A (en) * 1987-08-26 1991-03-05 Ohio State University Research Foundation Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
ATE142489T1 (de) * 1990-05-16 1996-09-15 Zbigniew Walaszek Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen

Also Published As

Publication number Publication date
EP0528950B1 (de) 1996-09-11
US5561160A (en) 1996-10-01
EP0528950A1 (de) 1993-03-03
JPH06504259A (ja) 1994-05-19
DE69122099T2 (de) 1997-04-17
EP0528950A4 (en) 1993-03-24
US5364644A (en) 1994-11-15
CA2080818A1 (en) 1991-11-17
EP0730862A1 (de) 1996-09-11
DE69122099D1 (de) 1996-10-17
WO1991018593A1 (en) 1991-12-12

Similar Documents

Publication Publication Date Title
ATE142489T1 (de) Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE123943T1 (de) Mittel zur behandlung und vorbeugung von bauchentzündungen, die als wirkstoff zink-l- carnosin-salze oder -komplexe enthalten.
HK1004257A1 (en) Use of droloxifene in the treatment of bone diseases
DE69422450D1 (de) Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DE3852773T2 (de) Zusammensetzungen und Verfahren zur Behandlung von Magen-Darmstörungen.
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
GR3026369T3 (en) Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist.
DE69229442T2 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69521536T2 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
DE69327328T2 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
KR890003390A (ko) 골다공증 및 관련된 장해의 치료방법
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
ATE193450T1 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenbrüchen
DE69528068D1 (de) Conagenine zur prävention und behandlung von diarrhöe
ATE245421T1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
KR890007737A (ko) 진토작용을 하는 약제